Table 2.
Clinical and biological characteristics according to CAD severity
| Variabl | Total n = 1537 | Single-vessel CAD (n = 784) | Multi-vessel CAD (n = 753) | P value |
|---|---|---|---|---|
| Age, years | 67.69 ± 10.15 | 67.53 ± 10.16 | 67.87 ± 10.13 | 0.282 |
| Sex, n (%) | < 0.001 | |||
| Male | 820 (53.4%) | 369 (47.1%) | 451 (59.9%) | |
| Female | 717 (46.6%) | 415 (52.9%) | 302 (40.1%) | |
| BMI, kg/m2 | 24.66 ± 2.97 | 23.93 ± 2.84 | 25.42 ± 2.92 | < 0.001 |
| SBP, mmHg | 145.69 ± 20.67 | 145.01 ± 19.32 | 146.40 ± 21.96 | 0.188 |
| DBP, mmHg | 84.15 ± 11.89 | 84.03 ± 11.55 | 84.27 ± 12.24 | 0.784 |
| Drinking, n (%) | 151 (9.8%) | 81 (10.3%) | 70 (9.3%) | 0.495 |
| Smoking, n (%) | 492 (32.0%) | 213 (27.2%) | 279 (37.1%) | < 0.001 |
| Glucose metabolism state, n (%) | < 0.001 | |||
| NGR | 444 (28.9%) | 245 (31.3%) | 199 (26.4%) | |
| Pre-DM | 571 (37.2%) | 318 (40.6%) | 253 (33.6%) | |
| DM | 522 (34.0%) | 221 (28.2%) | 301 (40.0%) | |
| NAFLD, n (%) | 169 (11.0%) | 76 (9.7%) | 93 (12.4%) | 0.096 |
| Hyperuricemia, n (%) | 231 (15.0%) | 110 (14.0%) | 121 (16.1%) | 0.264 |
| H-type hypertension, n (%) | 912 (59.3%) | 443 (56.5%) | 469 (62.3%) | 0.021 |
| History of hypertension medication, n (%) | ||||
| CCB | 615 (40.0%) | 305 (38.9%) | 310 (41.2%) | 0.365 |
| β-receptor blocker | 194 (12.6%) | 105 (13.4%) | 89 (11.8%) | 0.353 |
| ACEI/ARB | 345 (22.4%) | 179 (22.8%) | 166 (22.0%) | 0.712 |
| Laboratory indicators | ||||
| HbA1c (%) | 6.46 ± 1.36 | 6.29 ± 1.19 | 6.64 ± 1.50 | < 0.001 |
| FPG (mmol/L) | 6.37 (5.27–8.37) | 5.87 (5.11–7.16) | 7.13 (5.56–9.74) | < 0.001 |
| Homocystein (μmol/L) | 16.09 (12.92–20.57) | 15.70 (12.71–19.61) | 16.79 (13.09–21.42) | 0.001 |
| Hemoglobin (g/L) | 134.52 ± 16.20 | 133.99 ± 16.05 | 135.09 ± 16.35 | 0.257 |
| Platelet (10^9/L) | 211 (175–250) | 209 (173–246) | 214 (177–257) | 0.021 |
| ALB (g/L) | 42.59 ± 3.81 | 42.83 ± 3.72 | 42.35 ± 3.89 | 0.018 |
| TC (mmol/L) | 4.51 (3.71–5.31) | 4.45 (3.64–5.17) | 4.60 (3.76–5.47) | 0.003 |
| TG (mmol/L) | 1.64 (1.07–2.42) | 1.47 (0.99–2.16) | 1.87 (1.21–2.69) | < 0.001 |
| LDL-C (mmol/L) | 2.45 (1.85–3.06) | 2.38 (1.80–2.95) | 2.50 (1.92–3.19) | 0.001 |
| HDL-C (mmol/L) | 1.2 (1.01–1.46) | 1.24 (1.05–1.50) | 1.16 (0.97–1.39) | < 0.001 |
| UA (μmol/L) | 364 (299–443) | 347 (286–433) | 379 (317–449) | < 0.001 |
| Creatinine (μmol/L) | 69.0 (56.9–84.6) | 67.1 (55.2–82.2) | 70.7 (59.3–86.4) | < 0.001 |
| Cystatin C (mg/L) | 0.94 (0.79–1.13) | 0.92 (0.78–1.10) | 6.58 (5.58–7.99) | 0.003 |
| Gensini score | 16 (7–32) | 8 (5–12) | 31 (20–46) | < 0.001 |
| TyG-BMI index | 222.76 (201.63–246.93) | 211.59 (192.47–233.25) | 233.23 (213.20–258.31) | < 0.001 |
Data are presented as median (interquartile) or number (proportion, %)
SBP: systolic blood pressure; DBP: diastolic blood pressure; NAFLD: nonalcoholic fatty liver disease; CCB: calcium channel blocker; ACEI: angiotensin converting enzyme inhibitors; ARB: angiotensin receptor blocker; HbA1c: glycated hemoglobin; FBG: fasting blood glucose; TG: triglycerides; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; UA: Uric acid; NGR: normal glucose regulation; Pre-DM: pre-diabetes; DM: diabetes mellitus